Problems with the PTH assays

Cavalier, Étienne; Delanaye, Pierre; Nyssen, Laurent; Souberbielle, Jean‐Claude

doi:10.1016/j.ando.2015.03.018

Cited by 25 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The poor performance of current PTH assays is due to the posttranslational modification of PTH, in particular oxidation at Met8 and Met18 of the PTH molecule [1,13] ( Fig. 2 ), since patients with CKD have a huge burden of oxidative stress [14][15][16][17] .…”

mentioning

confidence: 99%

Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD

Hocher¹

2017

Kidney Dis

View full text Add to dashboard Cite

Background: Chronic kidney disease-mineral and bone disorder (CKD-MBD) patients have a huge morbidity and mortality. Only relatively minor progress in therapeutic strategies has been made in the past decades. This is at least partially due to a lack of predictive diagnostic tools allowing personalized treatment of CKD-MBD patients. Summary: In this review we describe recent progress in the diagnosis of disturbances of calcium and phosphate metabolism in patients with CKD-MBD, measuring biological active nonoxidized parathyroid hormone as well as the overall likelihood of a patient to get calcified. Key Message: There is hope. The new tools have the potential of allowing personalized therapy for the treatment of CKD-MBD and hence improving outcome.

show abstract

mentioning

confidence: 99%

Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD

Hocher¹

2017

Kidney Dis

View full text Add to dashboard Cite

show abstract

“…Measurement of PTH was not possible in these cases; however, it is likely these horses would have had increased plasma PTH concentrations. While PTH assays are available for horses, there are recognised problems with PTH measurement associated with PTH stability and diurnal variation in PTH concentrations (Estepa et al 2003;Toribio et al 2005;Hanon et al 2013;Cavalier et al 2015).…”

Section: Discussionmentioning

confidence: 99%

Acute and chronic oxalate toxicity in Miniature Horses associated with soursob (Oxalis pes‐caprae) ingestion

Herbert¹,

Dittmer

2016

Equine Veterinary Education

View full text Add to dashboard Cite

Summary Over the period of 11 years (2004–2015) 14 miniature horses in six separate outbreaks presented with clinical signs consistent with acute or chronic oxalate toxicity. All animals had access to Oxalis pes‐caprae or soursob. Miniature horses with acute oxalate toxicity and hypocalcaemia had muscle fasciculations, tremors and synchronous diaphragmatic flutter; these horses responded to treatment with intravenous and oral calcium. Chronic oxalate toxicity was associated with ill‐thrift, stiffness, enlarged heads, kyphosis and neurological signs. These animals had normal serum calcium concentrations, but increased serum alkaline phosphatase activity. Radiographs indicated that affected animals had bones that were osteopenic, often with pathological fractures. Bones that were examined histologically showed increased osteoclastic and osteoblastic activity, consistent with nutritional secondary hyperparathyroidism and fibrous osteodystrophy. These animals were treated, with mixed success, with oral calcium supplementation. A palatability trial showed that horses will readily eat soursobs, and measured total oxalate concentrations in soursobs collected from five different properties ranged from 13.5 to 18.5%. The presentation of affected animals with either acute hypocalcaemia or nutritional secondary hyperparathyroidism, together with a history of grazing soursobs, suggest that acute and chronic oxalate toxicity are the cause of the clinical signs seen in affected miniature horses.

show abstract

“…Recent reviews point out these issues and promote the development of a reference quantification method to harmonize PTH assays. Methods using LC–MS for PTH quantitation were published .…”

Section: Introductionmentioning

confidence: 99%

Highly sensitive and selective separation of intact parathyroid hormone and variants by sheathless CE‐ESI‐MS/MS

et al. 2019

Self Cite

View full text Add to dashboard Cite

Parathyroid hormone (PTH) is a common clinical marker whose quantification relies on immunoassays, giving variable results as batch, brand, or target epitope changes. Sheathless CE‐ESI‐MS, combining CE resolution power and low‐flow ESI sensitivity, was applied to the analysis of PTH in its native conformation in the presence of related forms. Fused silica and neutral‐coated capillaries were investigated, as well as preconcentration methods such as transient isotachophoresis, field‐amplified sample injection (FASI), and electrokinetic supercharging (EKS). The method for the separation of PTH and its variants was first developed using fused‐silica capillary with UV detection. An acidic BGE was used to separate 1–84 PTH (full length), 7–84 PTH, and 1–34 PTH. Acetonitrile was added to the BGE to reduce peptide adsorption onto the capillary wall and transient isotachophoresis was used as analyte preconcentration method. The method was then transferred to a sheathless CE‐ESI‐MS instrument. When using a fused silica capillary, CE‐MS was limited to μg/mL levels. The use of a neutral coating combined with FASI or EKS allowed a significant increase in sensitivity. Under these conditions, 1–84 PTH, 7–84 PTH, and 1–34 PTH were detected at concentrations in the low ng/mL (FASI) or pg/mL (EKS) range.

show abstract

Problems with the PTH assays

Cited by 25 publications

References 35 publications

Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD

Hope for CKD-MBD Patients: New Diagnostic Approaches for Better Treatment of CKD-MBD

Acute and chronic oxalate toxicity in Miniature Horses associated with soursob (Oxalis pes‐caprae) ingestion

Highly sensitive and selective separation of intact parathyroid hormone and variants by sheathless CE‐ESI‐MS/MS

Contact Info

Product

Resources

About